Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection

Clinical Pharmacology and Therapeutics
N R HartmanD G Johns

Abstract

This article describes the pharmacokinetics of 2',3'-dideoxyadenosine (ddA) and 2',3'-dideoxyinosine (ddI) as determined during phase I clinical trials in patients with acquired immunodeficiency syndrome and acquired immunodeficiency syndrome-related complex. Drug levels were determined by HPLC in plasma, cerebrospinal fluid, and urine after administration of the drugs either intravenously or as an oral liquid given with antacid. ddA was metabolized rapidly and quantitatively to ddI to such an extent that ddA was undetectable in the plasma even during continuous intravenous administration of ddA. The plasma kinetics of ddI were generally monoexponential and were characterized by a half-life of 38 minutes. This probably does not accurately reflect the kinetics of the active species of ddI, which appears to be 2',3'-dideoxyadenosine triphosphate, formed intracellularly. Oral bioavailability was 38% for oral liquid given with antacid. The total body clearance averaged 1.00 L/kg/hr, with a volume of distribution of 1.01 L/kg. Approximately 36% of the intravenous dose could be recovered unchanged in the urine. The level of ddI in the cerebrospinal fluid 1 hour after drug infusion averaged 21% of that of the simultaneous plasma level...Continue Reading

Citations

Dec 1, 1991·The Journal of Pharmacy and Pharmacology·A R SwaglerJ M Gallo
Mar 1, 1992·British Journal of Clinical Pharmacology·D J BackR Macleod
Sep 1, 1994·British Journal of Clinical Pharmacology·G I HendersonS Schenker
Jan 1, 1994·Critical Reviews in Clinical Laboratory Sciences·B Stretcher
Nov 14, 1998·AIDS·R H EntingP Portegies
Aug 26, 1998·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·A CatoR Granneman
Aug 3, 2002·CNS Drugs·Heather E WynnCourtney V Fletcher
Jul 10, 2012·Expert Opinion on Drug Delivery·Ali Demir Sezer, Erdal Cevher
May 1, 1992·The Annals of Pharmacotherapy·M J SheltonG D Morse
Oct 16, 1992·Pharmaceutisch Weekblad. Scientific Edition·R M FranssenJ H Beijnen
Oct 1, 1994·Journal of Clinical Pharmacology·E K HusseyG L Evans
Apr 16, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jouko SavolainenBradley D Anderson
Jul 1, 1991·British Journal of Clinical Pharmacology·S M SimA M Breckenridge
Jul 1, 1993·British Journal of Clinical Pharmacology·M BarryF Nye
Feb 12, 2013·Bioanalysis·Robin DiFrancescoGene D Morse
Oct 1, 1992·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M W FriedJ H Hoofnagle
May 20, 2005·The Journal of Pharmacology and Experimental Therapeutics·Philip L LorenziGordon L Amidon
Aug 29, 2003·Journal of the International Association of Physicians in AIDS Care : JIAPAC·David A Cooper
Aug 22, 2002·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Masahiko OkiyamaSachi Fukunishi
Jun 6, 2000·Advanced Drug Delivery Reviews·X Li, W K Chan

❮ Previous
Next ❯

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.